Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 11/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SCN1A | P35498 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17031936 | 1.00 | MAPKAPK2 (0.40) | MAPKAPK2GAATNFHSD11B1CNR1 | |
| SCHEMBL18673898 | 1.00 | MAPKAPK2 (0.40) | MAPKAPK2GAATNFHSD11B1CNR1 | |
| SCHEMBL14863768 | 1.00 | MAPKAPK2 (0.40) | MAPKAPK2GAATNFHSD11B1CNR1 | |
| SCHEMBL14831204 | 0.89 | BACE1 (0.36) | MAPKAPK2 | |
| SCHEMBL14831203 | 0.89 | BACE1 (0.36) | MAPKAPK2 | |
| SCHEMBL27965854 | 0.89 | BACE1 (0.36) | MAPKAPK2 | |
| SCHEMBL18635816 | 0.89 | BACE1 (0.36) | MAPKAPK2 | |
| SCHEMBL17031973 | 0.89 | BACE1 (0.36) | MAPKAPK2 | |
| SCHEMBL15638876 | 0.89 | BACE1 (0.36) | MAPKAPK2 | |
| SCHEMBL17041210 | 0.87 | MAPKAPK2 (0.32) | MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2766352-B1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK UHN (CA) | 2018-06-06 | — | — | EP | disclosed |
| US-9603889-B2 | IAP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-28 | — | — | US | disclosed |
| US-9603889-B2 | IAP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-28 | — | — | US | disclosed |
| EP-2903998-B1 | IAP ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2903998-B1 | IAP ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9580390-B2 | Indazole compounds as kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-28 | — | — | US | disclosed |
| US-20150238558-A1 | IAP ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2015-08-27 | — | — | US | disclosed |
| EP-2766352-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | University Health Network (UHN) (CA) | 2014-08-20 | — | — | EP | disclosed |
| US-20140051679-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERISTY HEALTH NETWORKS (CA) | 2014-02-20 | — | — | US | disclosed |
| WO-2013053051-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-18 | — | — | WO | disclosed |
| WO-2009083526-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051679-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | MAP3K7, MAP3K1, MAP3K20 | MAPKAPK2 23/4885GAA 1381/4885TNF 4259/4885 |
| US-20150238558-A1 | IAP ANTAGONISTS | XIAP, BIRC5, API5 | MAPKAPK2 784/4885GAA 1710/4885TNF 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.